Lifecore Biomedical Inc (LFCR)

$5.83

-0.13

(-2.18%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Lifecore Biomedical Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 27.6M → 31.54M (in $), with an average increase of 12.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -12.06M → -36.13M (in $), with an average decrease of 80.9% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 50.3% return, outperforming this stock by 39.1%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 46.5% return, outperforming this stock by 97.7%

Performance

  • $5.81
    $5.96
    $5.83
    downward going graph

    0.43%

    Downside

    Day's Volatility :2.6%

    Upside

    2.18%

    downward going graph
  • $4.50
    $11.46
    $5.83
    downward going graph

    22.81%

    Downside

    52 Weeks Volatility :60.73%

    Upside

    49.13%

    downward going graph

Returns

PeriodLifecore Biomedical IncIndex (Russel 2000)
3 Months
-23.69%
0.0%
6 Months
-20.0%
0.0%
1 Year
11.19%
0.0%
3 Years
-49.96%
-20.1%

Highlights

Market Capitalization
181.3M
Book Value
- $0.14
Earnings Per Share (EPS)
-2.14
PEG Ratio
3.51
Wall Street Target Price
8.0
Profit Margin
-96.41%
Operating Margin TTM
-7.68%
Return On Assets TTM
-4.67%
Return On Equity TTM
-104.52%
Revenue TTM
103.3M
Revenue Per Share TTM
3.45
Quarterly Revenue Growth YOY
20.8%
Gross Profit TTM
27.3M
EBITDA
-9.9M
Diluted Eps TTM
-2.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.76
EPS Estimate Next Year
-0.43
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Lifecore Biomedical Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 37.22%

Current $5.83
Target $8.00

Company Financials

FY18Y/Y Change
Revenue
524.2M
↓ 1.51%
Net Income
24.8M
↑ 134.46%
Net Profit Margin
4.74%
↑ 2.75%
FY19Y/Y Change
Revenue
557.6M
↑ 6.36%
Net Income
2.1M
↓ 91.45%
Net Profit Margin
0.38%
↓ 4.36%
FY20Y/Y Change
Revenue
590.4M
↑ 5.88%
Net Income
-38.2M
↓ 1899.76%
Net Profit Margin
-6.47%
↓ 6.85%
FY21Y/Y Change
Revenue
544.2M
↓ 7.83%
Net Income
-32.7M
↓ 14.47%
Net Profit Margin
-6.0%
↑ 0.47%
FY22Y/Y Change
Revenue
185.8M
↓ 65.86%
Net Income
-97.4M
↑ 198.27%
Net Profit Margin
-52.44%
↓ 46.44%
FY23Y/Y Change
Revenue
185.8M
↑ 0.0%
Net Income
-46.1M
↓ 52.7%
Net Profit Margin
-24.8%
↑ 27.64%
Q2 FY22Q/Q Change
Revenue
47.6M
↓ 10.26%
Net Income
-36.7M
↑ 185.32%
Net Profit Margin
-76.98%
↓ 52.77%
Q3 FY22Q/Q Change
Revenue
47.6M
↑ 0.0%
Net Income
-36.7M
↑ 0.0%
Net Profit Margin
-76.98%
↑ 0.0%
Q4 FY22Q/Q Change
Revenue
38.8M
↓ 18.53%
Net Income
-12.4M
↓ 66.04%
Net Profit Margin
-32.08%
↑ 44.9%
Q1 FY23Q/Q Change
Revenue
43.4M
↑ 11.73%
Net Income
-12.1M
↓ 3.09%
Net Profit Margin
-27.83%
↑ 4.25%
Q2 FY23Q/Q Change
Revenue
27.6M
↓ 36.34%
Net Income
-15.5M
↑ 28.16%
Net Profit Margin
-56.02%
↓ 28.19%
Q1 FY24Q/Q Change
Revenue
31.5M
↑ 14.3%
Net Income
-36.1M
↑ 133.68%
Net Profit Margin
-114.53%
↓ 58.51%
FY18Y/Y Change
Total Assets
404.7M
↑ 13.04%
Total Liabilities
152.1M
↑ 17.16%
FY19Y/Y Change
Total Assets
519.1M
↑ 28.26%
Total Liabilities
248.9M
↑ 63.63%
FY20Y/Y Change
Total Assets
541.3M
↑ 4.28%
Total Liabilities
310.3M
↑ 24.63%
FY21Y/Y Change
Total Assets
502.9M
↓ 7.09%
Total Liabilities
300.1M
↓ 3.26%
FY22Y/Y Change
Total Assets
295.2M
↓ 41.31%
Total Liabilities
187.2M
↓ 37.62%
FY23Y/Y Change
Total Assets
295.4M
↑ 0.09%
Total Liabilities
187.3M
↑ 0.04%
Q2 FY22Q/Q Change
Total Assets
295.2M
↓ 9.34%
Total Liabilities
187.2M
↑ 3.14%
Q3 FY22Q/Q Change
Total Assets
295.2M
↑ 0.0%
Total Liabilities
187.2M
↑ 0.0%
Q4 FY22Q/Q Change
Total Assets
279.1M
↓ 5.45%
Total Liabilities
204.9M
↑ 9.45%
Q1 FY23Q/Q Change
Total Assets
285.8M
↑ 2.41%
Total Liabilities
188.9M
↓ 7.81%
Q2 FY23Q/Q Change
Total Assets
236.2M
↓ 17.37%
Total Liabilities
201.9M
↑ 6.91%
Q1 FY24Q/Q Change
Total Assets
255.2M
↑ 8.04%
Total Liabilities
257.0M
↑ 27.26%
FY19Y/Y Change
Operating Cash Flow
16.0M
↓ 19.01%
Investing Cash Flow
-96.8M
-
Financing Cash Flow
79.0M
↑ 494.54%
FY20Y/Y Change
Operating Cash Flow
-17.0M
↓ 206.37%
Investing Cash Flow
-23.9M
↓ 75.32%
Financing Cash Flow
40.0M
↓ 49.36%
FY21Y/Y Change
Operating Cash Flow
15.0M
↓ 188.12%
Investing Cash Flow
-10.9M
↓ 54.55%
Financing Cash Flow
-3.4M
↓ 108.54%
FY22Y/Y Change
Operating Cash Flow
-24.4M
↓ 262.48%
Investing Cash Flow
81.8M
↓ 853.21%
Financing Cash Flow
-57.0M
↑ 1567.77%
FY23Y/Y Change
Operating Cash Flow
-24.4M
↑ 0.0%
Investing Cash Flow
-4.2M
↓ 105.08%
Financing Cash Flow
-57.0M
↑ 0.0%
Q2 FY22Q/Q Change
Operating Cash Flow
36.0K
↓ 100.18%
Investing Cash Flow
-19.4M
↑ 0.0%
Financing Cash Flow
19.1M
↓ 140.65%
Q3 FY22Q/Q Change
Operating Cash Flow
36.0K
↑ 0.0%
Investing Cash Flow
206.0K
↓ 101.06%
Financing Cash Flow
19.1M
↑ 0.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.9M
↓ 8288.89%
Investing Cash Flow
-3.3M
↓ 1679.13%
Financing Cash Flow
8.8M
↓ 53.98%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.5M
↓ 48.0%
Investing Cash Flow
-3.3M
↑ 0.0%
Financing Cash Flow
3.9M
↓ 55.66%
Q2 FY23Q/Q Change
Operating Cash Flow
-12.7M
↑ 727.66%
Investing Cash Flow
6.4M
↓ 296.56%
Financing Cash Flow
2.4M
↓ 38.2%

Technicals Summary

Sell

Neutral

Buy

Lifecore Biomedical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lifecore Biomedical Inc
Lifecore Biomedical Inc
-5.25%
-20.0%
11.19%
-49.96%
-38.3%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.15%
26.64%
50.32%
46.7%
76.15%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
1.91%
2.16%
-0.35%
14.98%
14.98%
Zoetis Inc.
Zoetis Inc.
18.72%
-3.66%
-3.75%
-2.05%
67.86%
Viatris Inc.
Viatris Inc.
-2.58%
16.97%
15.73%
-28.65%
-32.93%
Catalent, Inc.
Catalent, Inc.
-1.94%
38.79%
46.52%
-46.41%
19.01%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lifecore Biomedical Inc
Lifecore Biomedical Inc
NA
NA
3.51
-0.76
-1.05
-0.05
NA
-0.14
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
38.49
38.49
0.44
4.06
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.37
28.37
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
33.54
33.54
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.33
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lifecore Biomedical Inc
Lifecore Biomedical Inc
Buy
$181.3M
-38.3%
NA
-96.41%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.3B
76.15%
38.49
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.9B
14.98%
28.37
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$79.6B
67.86%
33.54
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-32.93%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.0B
19.01%
211.02
-28.44%

Institutional Holdings

  • Wynnefield Capital Inc

    16.12%

  • Legion Partners Asset Management, LLC

    9.66%

  • Greenhaven Road Investment Management, L.P.

    7.75%

  • 22NW, LP

    5.75%

  • Cove Street Capital, LLC

    4.20%

  • Vanguard Group Inc

    3.88%

Company Information

landec corporation (nasdaq:lndc) is a leading innovator of diversified health and wellness solutions within the packaged food and biomaterial markets. apio, landec's food business, is the leader in branded, packaged fresh vegetables in north america, utilizing its proprietary breatheway® packaging technology to naturally extend the shelf life of fresh produce. apio combines this technology with the capabilities of a large national fresh produce supplier to offer healthy fresh vegetable products under the eat smart® brand to consumers through club and retail grocery stores. lifecore biomedical, landec's biomaterial business, is a fully integrated contract development and manufacturing organization (cdmo) that offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for fda regulated medical devices and drugs to customers for applications in a wide array of markets including ophthalmic, orthopedic and oncology. for more information abo

Organization
Lifecore Biomedical Inc
Employees
459
CEO
Mr. James G. Hall
Industry
Healthcare

Discover More

FAQs